Session Five: The next goal – towards Canada, France, Japan and the United States. Canada & France: Dr Etienne Hirsch, Director, Institute for Neurosciences, Cognitive sciences, Neurology and Psychiatry at INSERM and the French alliance for life and health science Aviesan & Dr Yves Joanette CIHR, Scientific Director, Canadian Institutes of Health Research (CIHR), Institute of Aging & World Dementia Council Member

1. Canada-France Legacy Event on Dementia
Prof. Yves Joanette
Scientific Director, CIHR Institute of Aging
Executive Director, CIHR International Collaborative
Research Strategy for Alzheimer's Disease
Dr. Etienne Hirsch
Director multi-agency thematic
institute (ITMO), neurosciences,
cognitive sciences, neurology and psychiatry,

2. 2
Canada-France Legacy Event on Dementia
Harnessing the Power of Discoveries:
Maximizing Academia and Industry Synergies
September 11–12, 2014
Ottawa, Canada
Co-organized by:

3. 3
 Canada and France have a strong history of working
collaboratively in the area of dementia research
 Canada and France have both developed collaborative models
involving academic and industrial partners in this sector (French
Alzheimer Plan, Canadian Consortium on Neurodegeneration in
Aging)
 Canada and France both have a track record of engaging in national
and international research consortia on dementia (e.g. the France-
chaired EU Joint Programme – Neurodegenerative Diseases;
Canada’s International Collaborative Research Strategy on
Alzheimer’s Disease)
Why Canada and France as Co-leads?

4. 4
Bringing Research Discoveries to Life
The Canada-France Legacy Event aims to develop an
action framework to address current challenges and barriers for enhanced
collaboration between researchers and industry.
developing new diagnostic and therapeutic approaches
facing the new pharmaceutical research environment
engaging medical devices, biotechnology and IT industries
taking full advantage of open innovation and big data

5. 5
Participants
40% academia
40% industry
20% policy makers / funders /
regulatory organizations /
patient organizations
Approximately 180 participants
from G7 countries and
other organizations:

6. 6
Program Overview
Day 1
Official Introductions
Session 1 – Setting the Stage
• An appeal for action from an individual with dementia
• Achieving an innovative Academia-Industry synergy - The real life example
• An arms-length view of the conditions for success to enhance synergy
between academia and industry
Session 2 – The Biotech and Venture Capital Challenge
• When Biotech companies take advantage of the Academia/Industry Synergy
– A real life example
• An example of a Biotech Hub – Fostering synergies between academia and
industry
• Conditions of Success for Biotech Hub: A comparison of different
jurisdictions

7. 7
Program Overview
Session 3 – The Pharmaceutical Sector - The New Paradigm
• Conditions of Success for Biotech Hub: A comparison of different
jurisdictions
• Bringing Academia and Pharmaceutical together in the European Space –
The Innovative Medicines Initiative
• Addressing the barriers for Innovative pharmaceutical Solution for Dementia
Session 4 – The New Opportunities from the Medical Device and IT
Industry
• The role of Academia for SMEs in Developing Tele-Medicine Solution for
Dementia – A real life example
• How can Established Information Technology Industry benefit from
enhanced synergy with Academia
• Putting academia and Industry Together in Europe for Dementia – The
Ambient Assisted Living Initiative
• How to ensure that e-Health and Tele-Medicine solutions for dementia will
support health systems

8. 8
Program Overview
Day 2
Session 5 – Solutions to Barriers – Part I
• The Regulatory Solutions Discussed at the Alzheimer's Disease
Summit - The Path to 2025, New York Academy of Sciences
• Solutions to the Regulatory Barriers – The Point of View of
Regulatory Bodies
Session 6 – Solutions to Barriers – Part II
• Status Report on the Big Data and Sustainability Initiative for large
scale research on Dementia
• The Role of Open Innovation to foster Academia/Industry Solutions
for Dementia
• Societal Acceptability of Innovative Research approach between
Academia and Industry - Results of the Canada/France Survey

9. 9
Contribution to the Priorities of the
World Dementia Council
The Canada-France Legacy Event will focus
primarily on the three following priorities:
• Finance
• Research collaboration
• Regulation and trials
• Sharing knowledge
• Health and care
• Awareness

10. 10
Canada-France Legacy Event on Dementia
Harnessing the Power of Discoveries:
Maximizing Academia and Industry Synergies
September 11–12, 2014
Ottawa, Canada
Co-organized by: